ROHTO PHARMACEUTICAL (4527) FY2026 Q3 Earnings Report

Quick View

Executive Summary

FY2025 Q3 results show revenue of 253.1 billion yen (YoY +12.0%), operating income of 33.6 billion yen (YoY +5.1%), ordinary income of 39.9 billion yen (YoY +20.5%), and net income of 28.3 billion yen (YoY +16.1%). The company demonstrated solid top-line growth driven by geographic expansion and M&A consolidations, while profitability metrics remained healthy with gross margin at 56.2% and operating margin at 13.3%. The divergence between operating income growth (+5.1%) and ordinary income growth (+20.5%) reflects significant contributions from non-operating items including dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen. Total assets increased to 460.7 billion yen from 437.0 billion yen, primarily due to goodwill additions from acquisitions totaling 33.6 billion yen in Asia and Europe segments. Equity ratio stands at 66.2%, maintaining a conservative capital structure, though notable shifts occurred in debt maturity profile with short-term borrowings rising 180.0 billion yen (+255.8%) while long-term debt decreased 16.4 billion yen (-92.0%).

Performance Drivers

Revenue increased 27.2 billion yen (+12.0% YoY) to 253.1 billion yen, driven by both organic growth and inorganic expansion through M&A. The Asia segment recorded the highest absolute growth with sales rising 22.5 billion yen (+30.8%) to 95.5 billion yen, reflecting the consolidation of Yu Yan Sang International subsidiary acquired in Q1, which contributed goodwill of 32.3 billion yen. Europe segment sales increased 3.9 billion yen (+28.8%) to 17.3 billion yen, supported by the acquisition of Mono company in Q2 adding goodwill of 1.4 billion yen. Japan segment, representing the core domestic business, showed modest growth of 0.4 billion yen (+0.3%) to 130.2 billion yen, indicating stable but mature domestic demand. America segment sales rose marginally 0.7 billion yen (+4.4%) to 16.8 billion yen. Geographic diversification progressed with international segments now accounting for approximately 48.5% of total sales compared to domestic Japan's 51.5%.

On the profit side, operating income grew 1.6 billion yen (+5.1%) to 33.6 billion yen, lagging revenue growth due to increased SG&A expenses which rose to 108.7 billion yen, representing 43.0% of sales. The operating margin contracted slightly from prior period levels, suggesting integration costs or investment spending associated with acquired entities. Segment operating profit analysis shows Asia contributed 13.3 billion yen (+26.4% YoY), Japan 18.0 billion yen (-2.8% YoY), America 1.0 billion yen (-6.2% YoY), and Europe 0.6 billion yen (-40.4% YoY), indicating profit mix shifts toward Asian operations while domestic and European profitability faced headwinds. A non-recurring impairment loss of 16 million yen was recorded in the Japan segment during the period.

Ordinary income expanded 6.8 billion yen (+20.5%) to 39.9 billion yen, significantly outpacing operating income growth due to net non-operating gains of approximately 6.3 billion yen. Key non-operating contributors include dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen, partially offset by interest expenses of 0.9 billion yen. Net income reached 28.3 billion yen (+16.1% YoY), with profit before tax of 38.8 billion yen yielding an effective tax burden ratio of approximately 72.9%. The gap between ordinary income (39.9 billion yen) and net income (28.3 billion yen) reflects normal tax incidence without material extraordinary items below the line.

This represents a revenue up, profit up pattern, though profit growth trails revenue growth due to elevated operating expenses and integration-related costs from recent acquisitions.

Segment Analysis

Japan segment generated revenue of 130.2 billion yen and operating income of 18.0 billion yen, representing the largest segment by revenue share at 51.5% and operating profit share at 54.7%, establishing it as the core business. Operating margin for Japan stands at 13.8%, representing healthy profitability despite year-over-year operating income decline of 2.8%. Asia segment produced revenue of 95.5 billion yen with operating income of 13.3 billion yen, yielding an operating margin of 13.9%, slightly above Japan's margin and showing strong momentum with operating income growth of 26.4% YoY driven by the Yu Yan Sang consolidation. America segment recorded revenue of 16.8 billion yen and operating income of 1.0 billion yen with margin of 6.0%, materially below other segments and declining 6.2% YoY, indicating margin pressure in this market. Europe segment achieved revenue of 17.3 billion yen but operating income of only 0.6 billion yen, translating to a notably low margin of 3.3% and representing a sharp 40.4% profit decline YoY despite strong revenue growth, suggesting integration challenges or investment phase costs from the Mono acquisition. The margin differential is material, with Japan and Asia maintaining mid-teens profitability while America and Europe operate at mid-to-low single-digit margins, highlighting geographic profit quality variance and the need for operational improvement in Western markets.

Key Metrics

[Profitability] ROE of 9.3% remained stable year-over-year, supported by net profit margin of 11.2% (net income 28.3 billion yen divided by revenue 253.1 billion yen) and operating margin of 13.3%. DuPont decomposition shows ROE of 9.3% driven by net margin of 11.2%, asset turnover of 0.549, and financial leverage of 1.51 times, indicating conservative capital structure with profitability primarily generated through margin rather than asset velocity or leverage. EBIT margin stands at 13.3% with interest burden ratio of 1.155 and tax burden ratio of 0.729, reflecting limited interest drag and normal tax incidence. Gross profit margin reached 56.2%, demonstrating strong pricing power or cost efficiency in core operations. [Cash Quality] Cash and deposits totaled 74.1 billion yen against short-term debt of 25.0 billion yen, providing cash coverage of 2.96 times for short-term borrowings. However, working capital metrics show deterioration with receivables turnover suggesting extended collection periods and inventory levels rising to 37.3 billion yen. [Investment Efficiency] Total asset turnover of 0.549 reflects capital-intensive pharmaceutical operations, consistent with industry characteristics but indicating room for efficiency improvement. Goodwill and intangible asset additions from M&A activities totaling 33.6 billion yen will require monitoring for impairment risk and return realization. [Financial Health] Equity ratio of 66.2% represents strong solvency with total equity of 304.9 billion yen supporting total assets of 460.7 billion yen. Current ratio of 203.1% and quick ratio of 169.1% indicate robust short-term liquidity. Debt-to-equity ratio of 0.09 confirms conservative leverage, though interest coverage ratio of 36.8 times (EBIT 33.6 billion yen divided by interest expense 0.9 billion yen) demonstrates ample earnings protection for debt service.

Cash Flow Analysis

Cash and deposits increased 14.3 billion yen year-over-year to 74.1 billion yen, reflecting accumulation despite significant M&A outflows for acquisitions. Operating profit growth of 1.6 billion yen and strong profitability contributed to cash generation capacity, though actual operating cash flow figures are not disclosed for the quarterly period. Working capital movements show mixed signals with accounts receivable rising to 53.8 billion yen and inventories increasing to 37.3 billion yen, suggesting cash tied up in operating cycle and potential efficiency concerns. On the investing side, balance sheet analysis indicates substantial cash deployment for acquisitions generating goodwill of 33.6 billion yen, representing major strategic investment activity during the nine-month period. Financing activities show notable restructuring with short-term borrowings surging 18.0 billion yen to 25.0 billion yen while long-term borrowings decreased 16.4 billion yen to 1.4 billion yen, indicating debt maturity profile shift toward short-term funding. The short-term liabilities ratio of 94.6% highlights refinancing exposure, though cash coverage of 2.96 times against short-term debt provides cushion. Net debt position remains modest given total interest-bearing debt of 26.5 billion yen against cash of 74.1 billion yen, implying net cash position of 47.6 billion yen and strong balance sheet flexibility for ongoing strategic investments or shareholder distributions.

Earnings Quality

Ordinary income of 39.9 billion yen versus operating income of 33.6 billion yen indicates non-operating net contribution of approximately 6.3 billion yen, representing 15.8% uplift to operating profit and 2.5% of revenue. This comprises primarily equity method gains, dividend income of 4.4 billion yen, interest income of 0.8 billion yen, and foreign exchange gains of 1.5 billion yen, partially offset by interest expenses of 0.9 billion yen and other non-operating costs. The dividend and interest income streams suggest investment portfolio holdings contributing recurring non-operating earnings, while FX gains of 1.5 billion yen introduce volatility depending on exchange rate movements. Non-operating income of 6.3 billion yen represents 2.5% of total revenue, a material but not excessive proportion, though reliance on dividend income and FX gains raises questions about earnings sustainability if market conditions shift. The operating earnings base of 33.6 billion yen provides the core recurring foundation, with non-operating items enhancing but not substituting for operational performance. One-time factors include the 16 million yen impairment loss in Japan segment, immaterial to overall results. Without disclosed operating cash flow data, direct accruals quality assessment is constrained, though the strong cash position of 74.1 billion yen and healthy current ratio of 203.1% suggest underlying cash generation supports reported earnings. However, working capital deterioration indicated by rising receivables and inventories warrants monitoring for potential earnings quality concerns if collections or inventory turnover continue weakening.

Guidance Update

Full-year guidance targets revenue of 340.5 billion yen, operating income of 40.5 billion yen, and ordinary income of 46.5 billion yen. Q3 cumulative progress shows revenue achievement of 74.3% (253.1 billion yen of 340.5 billion yen target), operating income achievement of 82.9% (33.6 billion yen of 40.5 billion yen target), and ordinary income achievement of 85.7% (39.9 billion yen of 46.5 billion yen target). At the standard three-quarter mark of 75%, operating income and ordinary income are tracking 7.9 percentage points and 10.7 percentage points ahead of pace respectively, indicating conservative guidance or front-loaded profitability. Revenue progress of 74.3% slightly trails the 75% benchmark by 0.7 percentage points, suggesting modest fourth-quarter acceleration needed or potential minor shortfall risk. The operating income run-rate implies Q4 operating income of approximately 6.9 billion yen required to meet full-year target, compared to Q3 nine-month actual of 33.6 billion yen, representing deceleration which may reflect seasonality or planned investment timing. Ordinary income similarly requires Q4 contribution of 6.6 billion yen, achievable given the strong non-operating income trends observed. Full-year EPS guidance of 146.04 yen compares to nine-month actual of 125.15 yen, implying Q4 EPS contribution of approximately 20.89 yen, which appears reasonable given historical patterns. The annual dividend forecast of 23.00 yen comprises interim dividend of 16.00 yen and expected year-end dividend of 20.00 yen, though this represents an inconsistency as 16.00 plus 20.00 totals 36.00 yen; clarification may be needed on interim versus second-quarter interim treatment. Overall guidance appears on track with profit metrics running ahead of schedule, though revenue execution in Q4 warrants attention to ensure full-year target achievement.

Shareholder Returns

Annual dividend forecast stands at 23.00 yen per share for the full fiscal year. Based on full-year forecast EPS of 146.04 yen, the payout ratio calculates to 15.8%, representing a conservative distribution policy with substantial earnings retention for reinvestment. Comparing to the nine-month actual EPS of 125.15 yen and annualizing the 23.00 yen dividend yields a payout ratio of approximately 30.1% when adjusted for partial-year earnings, suggesting the company maintains flexibility in dividend policy relative to earnings trajectory. Year-over-year dividend comparison is not explicitly provided in the dataset, preventing assessment of dividend growth trends. No share buyback program information is disclosed for the current period, indicating dividends represent the sole form of cash return to shareholders. Total return ratio therefore equals the payout ratio at 15.8% based on forecast earnings, leaving significant cash flow retention of 84.2% for organic growth investment, M&A activity, or balance sheet strengthening. The conservative payout ratio of 15.8% provides substantial dividend sustainability cushion even if earnings face headwinds, supported by strong cash position of 74.1 billion yen and robust equity base of 304.9 billion yen generating ample coverage. The dividend policy appears oriented toward growth investment given active M&A strategy evidenced by 33.6 billion yen goodwill additions, with shareholder distributions maintained at modest but stable levels.

Risk Factors

Refinancing risk emerges as the primary financial concern with short-term liabilities ratio reaching 94.6% of total liabilities and short-term borrowings surging 255.8% year-over-year to 25.0 billion yen while long-term debt collapsed 92.0% to 1.4 billion yen. This debt maturity concentration creates exposure to interest rate fluctuations and credit market conditions upon refinancing, though current cash coverage of 2.96 times and interest coverage of 36.8 times provide near-term protection. Goodwill impairment risk warrants close monitoring given 33.6 billion yen of goodwill additions from recent M&A activity, particularly the 32.3 billion yen Yu Yan Sang acquisition and 1.4 billion yen Mono acquisition. Integration execution challenges and realization of projected synergies will determine whether carrying values remain supported, with Europe segment's 40.4% operating profit decline despite revenue growth signaling potential stress. Working capital management deterioration poses operational risk as receivables and inventory levels rise, with quality metrics flagging material DSO, DIO, and cash conversion cycle degradation. Extended collection periods tie up cash and increase bad debt exposure, while inventory buildup raises obsolescence risk and carrying costs, particularly relevant in pharmaceutical and health products sectors with product lifecycle and expiration considerations. These working capital headwinds could strain liquidity if not addressed through enhanced collection efforts and inventory optimization.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis)

Profitability: The company's ROE of 9.3% significantly outperforms the pharmaceutical industry median of -35.8% for 2025-Q3, placing it in a strong competitive position. Operating margin of 13.3% substantially exceeds the industry median of -218.2%, demonstrating superior operational efficiency and cost management relative to peer pharmaceutical companies. Net profit margin of 11.2% contrasts sharply with industry median of -216.8%, highlighting the company's ability to generate consistent bottom-line profitability while many industry participants face losses.

Financial Health: Equity ratio of 66.2% closely aligns with industry median of 67.8%, indicating comparable capital structure conservatism within sector norms. Current ratio of 203.1% falls well below industry median of 662.0%, though remains healthy in absolute terms at 2.0 times coverage, suggesting the company operates with tighter but adequate liquidity management compared to more conservative industry peers.

Efficiency: Asset turnover of 0.549 substantially exceeds industry median of 0.17, demonstrating superior asset utilization and revenue generation efficiency per unit of invested capital. This metric positions the company as a high-efficiency operator within a capital-intensive pharmaceutical sector. Inventory turnover of approximately 130 days (calculated from balance sheet) compares favorably to industry median of 281.6 days, indicating faster inventory velocity and working capital efficiency.

Growth: Revenue growth of 12.0% year-over-year significantly outpaces industry median decline of -12.5%, establishing the company as a growth leader through both organic expansion and M&A execution while sector peers face contraction. EPS growth of 15.4% substantially exceeds industry median decline of -6.0%, reflecting strong earnings momentum.

The company demonstrates exceptional relative performance across profitability, efficiency, and growth dimensions, operating well above industry benchmarks and positioned in the top quartile of pharmaceutical sector participants based on fundamental financial metrics.

(Industry: Pharmaceutical sector, N=13 companies for most metrics, Comparison period: 2025-Q3, Source: Proprietary analysis)

Key Takeaways from Earnings

The company exhibits strong fundamental performance with revenue growth of 12.0% substantially outpacing the pharmaceutical industry median decline of 12.5%, while maintaining industry-leading profitability with operating margin of 13.3% versus sector median of negative 218.2%. Geographic diversification strategy shows tangible progress with international segments expanding to 48.5% of revenue mix, driven by strategic M&A execution adding 33.6 billion yen in goodwill from Asia and Europe acquisitions that enhance market access and product portfolio breadth.

Financial structure warrants attention as debt maturity profile shifted materially toward short-term funding, with short-term borrowings increasing 255.8% to 25.0 billion yen while long-term debt decreased 92.0% to 1.4 billion yen, creating refinancing exposure despite strong interest coverage of 36.8 times and cash coverage of 2.96 times indicating near-term debt service capacity remains adequate. Working capital efficiency deterioration represents an operational concern with receivables and inventory levels rising, though strong cash generation capacity evidenced by 74.1 billion yen cash position and robust 66.2% equity ratio provide financial flexibility to address operational optimization needs.

Full-year guidance progress tracking above pace for profitability metrics with operating income at 82.9% and ordinary income at 85.7% of annual targets through three quarters suggests potential for guidance upward revision or conservative forecasting, while dividend policy at 15.8% payout ratio provides substantial reinvestment capacity supporting ongoing M&A strategy and growth investments while maintaining shareholder distributions at sustainable levels with significant upside flexibility.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

Rohto Pharmaceutical delivered a solid FY2026 Q3 cumulative result, with double-digit sales growth and faster growth in profit attributable to owners, although operating-margin dilution and working-capital intensity remain key areas to monitor. Revenue rose 12.0% year on year to ¥253.1bn. Operating income increased 5.1% to ¥33.6bn, trailing revenue growth as the operating margin declined by 88bp to 13.3%. Gross profit increased 10.5% to ¥142.3bn, but the gross margin contracted by 76bp to 56.2%. SG&A expenses increased 12.3% to ¥108.7bn, marginally faster than revenue, limiting operating leverage. Ordinary income rose 20.5% to ¥39.9bn, materially outpacing operating income. This was supported by a ¥4.4bn dividend-income contribution, ¥1.5bn of foreign-exchange gains and ¥0.8bn of interest income. Profit attributable to owners rose 14.3% to ¥28.3bn, with the net margin expanding 22bp to 11.2%. The improvement in net margin despite weaker operating margin reflects the stronger non-operating income contribution rather than a broad-based improvement in core operating profitability. Net income also absorbed a net extraordinary loss of ¥1.1bn, principally a ¥1.1bn loss on valuation of investment securities, compared with a net extraordinary gain in the prior-year period. Japan remained the core business by segment profit, generating ¥18.0bn, or 53.5% of aggregate segment profit before eliminations. Asia was the principal growth engine, with revenue up 32.9% and segment profit up 26.4%, increasing its contribution to segment profit to 39.6%. In contrast, Japan segment profit declined 2.8%, while Americas and Europe profits fell 6.2% and 40.4%, respectively. The reported annualized ROE of 12.4% is in the good range, supported by a strong 11.2% net margin and conservative financial leverage of 1.51x. The balance sheet remains liquid, with a 203.1% current ratio and ¥74.1bn of cash and deposits. The principal forward implication is that full-year operating-income guidance looks achievable, but sustaining margin progression depends on restoring profitability in Japan, the Americas and Europe while converting rapidly growing Asian revenue into cash efficiently.

Profitability Analysis

The reported annualized DuPont ROE is 12.4%, decomposed into an 11.2% net profit margin, 0.732x asset turnover and 1.51x financial leverage. The return profile is therefore driven chiefly by a high net margin rather than leverage, consistent with the 62.3% capital adequacy ratio and 8.0% debt-to-capital ratio. Financial leverage is conservative and is not the primary source of shareholder returns. The annualized 0.732x asset turnover indicates that the company carries a meaningful asset base relative to sales, including ¥90.3bn of property, plant and equipment, ¥81.3bn of intangible assets and ¥53.8bn of investment securities. Operating margin decreased to 13.3% from 14.1% in the prior-year period, an 88bp contraction. Gross margin also declined to 56.2% from 57.0%, a 76bp contraction, indicating that most of the operating-margin pressure began above the SG&A line. SG&A grew 12.3%, slightly exceeding the 12.0% sales increase, which added modest negative operating leverage. Net margin nevertheless increased to 11.2% from 11.0%, because non-operating income rose to ¥8.1bn from ¥2.4bn. Dividend income of ¥4.4bn was particularly important, accounting for 54.6% of non-operating income. The extended DuPont tax burden was 0.729, equivalent to a 26.9% effective tax rate and within a normal range. The interest burden was 1.155 because non-operating income exceeded interest costs; interest coverage was a very strong 36.77x. Japan is the core segment, but its segment margin declined to 14.2% from 14.6% as segment profit fell despite modest revenue growth. Asia maintained the highest major-segment growth contribution, with a 14.6% segment margin versus 15.3% in the prior-year period. Europe had the weakest profitability at a 3.4% segment margin, down from 7.2%, while the Americas margin declined to 6.5% from 7.2%. The sustainability of consolidated net-margin expansion consequently depends less on recurring operating-margin gains and more on whether the elevated investment-income contribution recurs.

Growth Assessment

Revenue growth of 12.0% was led by Asia, where external sales rose ¥22.5bn to ¥91.1bn, up 32.9% year on year. Europe also expanded strongly, with sales up 28.0% to ¥17.2bn, although this did not translate into segment-profit growth. Americas sales increased 2.7% to ¥15.6bn, while Japan sales were broadly flat, rising only 0.3% to ¥126.7bn. Asia represented 48.6% of the consolidated year-on-year revenue increase, underlining its role as the major incremental growth contributor. Asia segment profit increased ¥2.8bn to ¥13.3bn, offsetting profit declines in Japan, the Americas and Europe. Consolidated operating-income growth of 5.1% was therefore substantially below sales growth, evidencing margin dilution during expansion. Ordinary-income growth of 20.5% and profit-attributable growth of 14.3% were stronger than operating-income growth, but their quality was enhanced by non-operating investment income rather than solely by operating execution. Against full-year guidance, Q3 cumulative sales achievement is 74.3%, broadly in line with the standard 75% progress rate. Operating-income achievement is 82.9%, or 7.9 percentage points ahead of the standard pace. Ordinary-income achievement is 85.7%, or 10.7 percentage points ahead of the standard pace, exceeding the 10-point threshold and reflecting the strong non-operating-income contribution. Profit attributable to owners achievement is also 85.7%, or 10.7 percentage points ahead of the standard pace. The guidance profile implies Q4 revenue of ¥87.4bn, operating income of ¥6.9bn, ordinary income of ¥6.6bn and profit attributable to owners of ¥4.7bn. This required Q4 operating margin is lower than the Q3 cumulative margin, suggesting room for normal seasonal costs, integration spending or a conservative guidance stance. Growth sustainability should be assessed through Asian margin retention, recovery in European profitability and progress in Japan, rather than through ordinary-income growth alone.

Financial Health

Financial health is strong overall. The current ratio is 203.1% and the quick ratio is 169.1%, comfortably above healthy liquidity benchmarks. Working capital totals ¥113.2bn, and cash and deposits of ¥74.1bn cover short-term loans by 2.96x. Total liabilities are ¥155.8bn against total equity of ¥304.9bn, while the reported debt-to-equity ratio is 0.51x and debt-to-capital is 8.0%. Interest-bearing debt is ¥26.5bn, comprising ¥25.0bn of short-term loans and ¥1.4bn of long-term loans. Interest coverage of 36.77x indicates ample capacity to service interest expense of ¥0.9bn. The principal liability-structure concern is refinancing risk: 94.6% of reported interest-bearing loans are short term, well above the 40% alert threshold. The root cause is the shift in the debt profile, with short-term loans increasing 255.8% year on year while long-term loans declined 92.0%. This maturity concentration is not presently a liquidity threat because cash substantially exceeds short-term loans, but it increases sensitivity to bank-credit availability and short-term funding conditions. The short-term debt increase appears to coincide with a materially larger asset base and should be monitored for whether it is temporary acquisition or working-capital financing. Intangible assets are ¥81.3bn, equal to 17.6% of total assets, remaining within the sub-20% balanced benchmark. Goodwill is ¥33.0bn, or 10.8% of equity and 7.2% of assets, both modest levels that do not indicate balance-sheet dependence on acquired value retention. Convertible bond-type bonds with subscription rights total ¥25.3bn and are an additional capital-structure instrument relevant to dilution and refinancing monitoring. No current-ratio or excessive-debt warning is indicated.

Notable B/S Changes

Short-term loans: +¥18.0bn (+255.8%) to ¥25.0bn - debt funding shifted materially toward short-term maturities, increasing refinancing concentration despite ample cash coverage. Long-term loans: -¥16.6bn (-92.0%) to ¥1.4bn - the reduction reinforces the short-term maturity concentration of reported interest-bearing loans. Intangible assets: +¥10.1bn to ¥81.3bn - an increase exceeding ¥5.0bn, raising the importance of monitoring returns and impairment resilience of intellectual-property and acquired intangible assets. Investment securities: +¥7.3bn to ¥53.8bn - an increase exceeding ¥5.0bn expands exposure to market-value volatility, as illustrated by the ¥1.1bn valuation loss recognized during the period.

Cash Flow Quality

The available balance-sheet and earnings data point to elevated working-capital absorption risk. Two high-inventory-day alerts require attention. The first alert indicates inventory days of 164 days against a 90-day threshold, while the second indicates 92 days against a 60-day threshold; both signal inventory intensity above their respective benchmarks. The root cause is the ¥37.3bn finished-goods balance, together with ¥23.3bn of raw materials and ¥5.5bn of work in process. Finished goods increased 2.6% year on year, while raw materials increased 15.8%, consistent with a larger inventory commitment to support growth. The 92-day measure is consistent with inventory relative to annualized cumulative cost of sales and remains elevated for a consumer-health and manufacturing business. The 164-day alert may reflect a broader inventory or alternative-cost-base definition, but it similarly indicates a need to monitor stock rotation. The long cash-conversion-cycle alert of 166 days exceeds the 120-day threshold. Its root cause is the combination of inventory intensity and a significant receivables base, including ¥53.8bn of trade receivables and ¥20.5bn of electronically recorded monetary claims. The impact is that strong accounting earnings may require greater reinvestment in working capital, reducing internally available cash for acquisitions, capital expenditure and shareholder distributions. Accounts payable of ¥22.4bn and electronically recorded obligations of ¥1.7bn provide only partial funding against these operating assets. The working-capital profile is particularly relevant while Asia expands rapidly, as faster growth can initially lengthen the cash conversion cycle. Cash conversion and inventory discipline are therefore central tests of whether regional growth is translating into high-quality cash earnings.

Dividend Sustainability

The company has paid an interim DPS of ¥21.0 and forecasts full-year DPS of ¥44.0. The forecast implies a year-end DPS of ¥23.0. Based on forecast basic EPS of ¥146.04, the full-year dividend payout ratio is approximately 30.1%. This is comfortably below the 60% sustainability benchmark and leaves substantial earnings retention capacity. The Q2 DPS of ¥21.0 represented a calculated 17.5% payout ratio against Q3 cumulative earnings, which is consistent with a conservative interim distribution approach. Retained earnings of ¥250.6bn provide a substantial equity buffer. The balance sheet also contains ¥74.1bn of cash and deposits, while debt-to-capital is only 8.0%. Dividend sustainability therefore appears well supported by earnings, retained capital and liquidity. The key variable for future distribution capacity is the conversion of earnings into cash amid the 166-day cash conversion cycle and elevated inventory-day alerts. The forecast dividend policy appears conservative relative to forecast earnings and does not appear to rely on additional borrowing.

Risk Assessment

Business risks include Asia is the largest incremental growth driver, with sales up 32.9%; execution risk lies in maintaining its 14.6% segment margin while scaling distribution, inventory and local operations., Japan remains the core business by segment profit, but revenue rose only 0.3% and segment profit fell 2.8%, creating risk that the largest profit pool does not provide operating leverage., Europe recorded a 40.4% decline in segment profit despite 28.0% sales growth, with margin falling to 3.4%; this points to pricing, mix, cost or integration pressure requiring reversal., Americas segment profit fell 6.2% despite 2.7% sales growth, with margin declining to 6.5%, leaving profitability exposed to regional cost inflation and competitive pressure., As a consumer-health and pharmaceutical-related manufacturer, the company faces product-demand volatility, channel inventory adjustments, pricing pressure and regulatory or quality-control risks..

Financial risks include Refinancing risk is elevated by a 94.6% short-term debt ratio. The current impact is contained by cash coverage of 2.96x and a 203.1% current ratio, but debt maturity concentration warrants monitoring., The 166-day cash conversion cycle and elevated 164-day and 92-day inventory-day alerts increase the risk that growth consumes cash faster than accounting earnings suggest., Investment securities total ¥53.8bn, and the period included a ¥1.1bn valuation loss on investment securities, exposing reported earnings and equity to market-value fluctuations., Convertible bond-type bonds with subscription rights of ¥25.3bn create potential dilution and capital-structure considerations..

Key concerns include Operating income grew only 5.1%, less than half the 12.0% revenue growth rate, with operating margin down 88bp to 13.3%., Ordinary-income outperformance was supported by ¥4.4bn of dividend income and other non-operating income; this contribution may be less repeatable than operating-profit growth., The company needs to demonstrate that rapid Asian sales growth can be delivered without further deterioration in inventory days and the cash conversion cycle., Goodwill and intangible assets total ¥114.3bn, or 24.8% of total assets; while goodwill/equity of 10.8% is healthy, the carrying value of acquired and intellectual-property assets remains relevant to impairment surveillance..

Investment Implications

Key takeaways include FY2026 Q3 cumulative sales and profit attributable to owners increased 12.0% and 14.3%, respectively, while operating-income growth was more modest at 5.1%., The operating margin contracted to 13.3%, but the net margin expanded to 11.2% due to stronger non-operating income., Asia is the principal growth contributor, whereas profit performance weakened in Japan, the Americas and Europe., Full-year sales guidance is tracking broadly on pace, while operating income, ordinary income and profit attributable to owners are ahead of standard Q3 progress rates., Liquidity and solvency are strong, but short-term funding concentration and working-capital intensity are the principal financial monitoring points..

Metrics to watch include Japan, Americas and Europe segment-profit recovery and segment-margin trends, Asia revenue growth, segment margin and inventory discipline, Operating margin relative to the 13.3% Q3 cumulative level, Dividend income and foreign-exchange gains within non-operating income, Inventory days, cash conversion cycle, receivables growth and cash conversion, Short-term loan balance, refinancing mix and cash-to-short-term-debt coverage, Investment-security valuation gains or losses and potential effects on extraordinary items.

Regarding relative positioning, Rohto Pharmaceutical combines above-benchmark net profitability, a good annualized ROE of 12.4%, strong liquidity and conservative debt-to-capital with a diversified regional sales base. Its 13.3% operating margin is in the good benchmark range but below the greater-than-15% excellent threshold, and recent growth quality is mixed: Asia is expanding strongly, while core Japan and Western regional profitability have weakened and non-operating income has become more influential in reported profit growth.